The traditional Chinese medicine in the treatment of gut microbiota and psoriasis

doi:10.3969/j.issn.1006-7795.2019.03.008

Abstract

Abstract: Psoriasis is a common systemic psychosomatic disorder characterized with immune-mediated chronic relapsing-remitting inflammation, which is closely related to intestinal flora dermatosis. The integrity and dynamic characteristics of the intestinal micro-ecology are consistent with the holistic view and perpetual motion view in traditional Chinese medicine (TCM). Some theories such as "The lung and the large intestine are interior-exteriorly related", "Lung relating to skin theory" and "Gut-brain-skin axis theory", and some researches on TCM maintaining the balance of intestinal microecology, provide a basis for exploring the TCM mechanism of diagnosis and treatment of psoriasis from the perspective of intestinal microecology. Based on a review of modern medical research on intestinal flora disorders and psoriasis vulgaris, this article interpreted the theories of TCM researches on intestinal flora of psoriasis, and explored the regulation function of intestinal microflora in TCM prevention and treatment of psoriasis. The new thought of TCM treating psoriasis by regulating intestinal microecology was proposed.

Key words: psoriasis, gut microbiota, traditional Chinese medicine research

CLC Number:

R275.1

Liu Xin, Zhang Guangzhong, Jiang Chunyan, Xiao Shiju, Tan Yong, Qu Jianhua, Chen Yanfei. The traditional Chinese medicine in the treatment of gut microbiota and psoriasis[J]. Journal of Capital Medical University, 2019, 40(3): 363-368.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.03.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I3/363

References

[1] Kulig P, Musiol S, Freiberger S N, et al. IL-12 protects from psoriasiform skin inflammation[J]. Nat Commun, 2016,7:13466.
[2] 吴佳佳, 武忠. 寻常型银屑病的治疗研究概况[J]. 中医临床研究, 2018,10(21):66-69.
[3] 荆夏敏, 吴刚, 荆宁. 银屑病的中医药疗法优势探讨[J]. 中国医学创新, 2010,7(28):157-158.
[4] Shen J, Obin M S, Zhao L. The gut microbiota, obesity and insulin resistance[J]. Mol Aspects Med, 2013,34(1):39-58.
[5] van Olden C, Groen A K, Nieuwdorp M. Role of intestinal microbiome in lipid and glucose metabolism in diabetes mellitus[J]. Clin Ther, 2015,37(6):1172-1177.
[6] Collins K H, Paul H A, Reimer R A, et al. Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development:studies in a rat model[J]. Osteoarthritis Cartilage, 2015,23(11):1989-1998.
[7] Salem I, Ramser A, Isham N, et al. The gut microbiome as a major regulator of the gut-skin axis[J]. Front Microbiol, 2018,9:1459.
[8] Omenetti S, Pizarro T T. The Treg/Th17 Axis:A dynamic balance regulated by the gut microbiome[J]. Front Immunol, 2015,6:639.
[9] De Preter V, Machiels K, Joossens M, et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD[J]. Gut, 2015,64(3):447-458.
[10] Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients[J]. Proc Natl Acad Sci U S A, 2008,105(43):16731-16736.
[11] Lopez-Siles M, Khan T M, Duncan S H, et al. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth[J]. Appl Environ Microbiol, 2012,78(2):420-428.
[12] Rooks M G, Garrett W S. Gut microbiota, metabolites and host immunity[J]. Nat Rev Immunol, 2016,16(6):341-352.
[13] Yasmine B, Timothy W H. Role of the microbiota in immunity and inflammation[J]. Cell, 2014,157(1):121-141.
[14] Lim K, Hyun Y M, Lambert-Emo K, et al. Neutrophil trails guide influenza-specific CD8⁺ T cells in the airways[J]. Science, 2015,349(6252):a4352.
[15] Groeger D, O'Mahony L, Murphy E F, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut[J]. Gut Microbes, 2013,4(4):325-339.
[16] Chen Y H, Wu C S, Chao Y H, et al. Lactobacillus pentosus GMNL-77 inhibits skin lesions in imiquimod-induced psoriasis-like mice[J]. J Food Drug Anal, 2017,25(3):559-566.
[17] Janssen A W, Kersten S. The role of the gut microbiota in metabolic health[J]. FASEB J, 2015,29(8):3111-3123.
[18] 廖苑津. 银屑病合并症的回顾性分析[D]. 杭州:浙江大学, 2018.
[19] Tang W H, Wang Z, Levison B S, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J]. N Engl J Med, 2013,368(17):1575-1584.
[20] Wang Z, Klipfell E, Bennett B J, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature, 2011,472(7341):57-63.
[21] Blandino G, Inturri R, Lazzara F, et al. Impact of gut microbiota on diabetes mellitus[J]. Diabetes Metab, 2016,42(5):303-315.
[22] Zuo T, KaymZuol T, Kamm M A, et al. Urbanization and the gut microbiota in health and inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2018,15(7):440-452.
[23] Scher J U, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease[J]. Arthritis Rheumatol, 2015,67(1):128-139.
[24] 杨雪琴. 银屑病心身疾病属性的基础研究和临床实践[J]. 武警医学, 2006,17(7):483-486.
[25] Sarkar A, Harty S, Lehto S M, et al. The microbiome in psychology and cognitive neuroscience[J]. Trends Cogn Sci, 2018,22(7):611-636.
[26] Carabotti M, Scirocco A, Maselli M A, et al. The gut-brain axis:interactions between enteric microbiota, central and enteric nervous systems[J]. Ann Gastroenterol, 2015,28(2):203-209.
[27] Gershon M D, Tack J. The serotonin signaling system:from basic understanding to drug development for functional GI disorders[J]. Gastroenterology, 2007,132(1):397-414.
[28] Bowe W, Patel N B, Logan A C. Acne vulgaris, probiotics and the gut-brain-skin axis:from anecdote to translational medicine[J]. Benef Microbes, 2014,5(2):185-199.
[29] Arck P, Handjiski B, Hagen E, et al. Is there a ‘gut-brain-skin axis’?[J]. Exp Dermatol, 2010,19(5):401-405.
[30] Budden K F, Gellatly S L, Wood D L, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2016,15(1):55-63.
[31] 张稳庵集注. 黄帝内经灵枢集注[M]. 1版. 上海:上海科学技术出版社, 1958:224.
[32] 余达, 杨坤, 王玉兴. 王玉兴教授治疗银屑病经验撷菁[J]. 中华中医药学刊, 2013,31(9):2028-2030.
[33] 申拱宸. 外科启玄[M]. 1版. 北京:人民卫生出版社, 1955:6.
[34] 王占国. 中医"脾"与消化道正常菌群[J]. 中国微生态学杂志, 1991,3(2):65-68.
[35] 郭思嘉, 姜东京, 李振岚, 等. 肠道菌群与常见胃肠道疾病关系及中药与微生态制剂治疗方法的研究进展[J]. 中草药,2018,49(18):4424-4431.
[36] 田代华整理. 黄帝内经素问[M]. 1版. 北京:人民卫生出版社, 2005:188.
[37] 靳晓非, 赵志亮. 肠道微生态与疾病及中医证候的关系[J]. 内蒙古医学杂志, 2009,41(S5):39-41.
[38] 付肖岩,劳绍贤,黄志新,等. 慢性腹泻脾胃湿热证与肠道菌群的关系[J]. 中国中西医结合消化杂志, 2005,13(4):223-225.
[39] 习婧. 不同中医证型的中重度痤疮和肠道菌群相关性的初步研究[D]. 武汉:湖北中医药大学, 2018.
[40] 梅一岚. 消化性溃疡中医辨证分型与肠道菌群变化的相关性研究[D]. 南京:南京中医药大学, 2018.
[41] 钟启福. 基于数据挖掘技术分析当代中医名家银屑病验方经验研究[D]. 南京:南京中医药大学, 2016.
[42] Codoñer F M, Ramírez-Bosca A, Climent E, et al. Gut microbial composition in patients with psoriasis[J]. Sci Rep, 2018,8:3812.
[43] 孟良艳, 陈秀琴, 石达友, 等. 四君子汤对脾虚大鼠肠道菌群多样性的影响[J]. 畜牧兽医学报, 2013,44(12):2029-2035.
[44] 王卓, 彭颖, 李晓波. 四君子汤对两种脾虚模型大鼠肠道菌群紊乱的影响[J]. 中国中西医结合杂志, 2009,29(9):825-829.
[45] 李海燕,董礼阳,杨景云. 四君子汤对急性肝损伤伴发菌群失调及内毒素血症的保护作用[J]. 中国微生态学杂志, 2005,17(2):100-101.
[46] 姚小华, 唐立, 林青, 等. 口炎清颗粒对小鼠肠道菌群失衡的调节作用[J]. 中国微生态学杂志, 2012,24(4):324-326.
[47] 朱文芳, 孙克伟, 陈斌, 等. 温阳解毒化瘀方对HBV相关肝衰竭患者肠道菌群的影响[J]. 中西医结合肝病杂志, 2014,24(4):214-216.
[48] Wang Y, Tong Q, Shou J W, et al. Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine[J]. Theranostics, 2017,7(9):2443-2451.